Abstract Number: 1295 • ACR Convergence 2025
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…Abstract Number: 1478 • ACR Convergence 2025
Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Cognitive dysfunction (CD) is a common but often underestimated complication in…Abstract Number: 1495 • ACR Convergence 2025
Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
Background/Purpose: The Physician Global Assessment (PGA) is used to measure disease activity on a 0–10 scale for many pediatric rheumatic conditions. However, the thresholds at…Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…Abstract Number: 1529 • ACR Convergence 2025
Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Background/Purpose: BMS-986353 (CC-97540; CD19 NEX-T) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that expresses the same CAR as lisocabtagene maraleucel (liso-cel); it…Abstract Number: 1548 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…Abstract Number: 1696 • ACR Convergence 2025
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types…Abstract Number: 1759 • ACR Convergence 2025
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Background/Purpose: SLE is an autoimmune disease that causes progressive multi-organ damage, leading to renal injury, or lupus nephritis (LN), in half of patients. Despite treatment,…Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…Abstract Number: 1896 • ACR Convergence 2025
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
Background/Purpose: Electronic cigarettes, or e-cigarettes, are inhalable aerosol nicotine-delivery devices increasingly used in addition or in place of cigarettes. Cigarette smoking is strongly associated with…Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…Abstract Number: 2224 • ACR Convergence 2025
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased risk of placental insufficiency and adverse pregnancy outcomes, even when the disease is clinically quiescent.…Abstract Number: 2389 • ACR Convergence 2025
A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study
Background/Purpose: SLE is a systemic autoimmune disease that can present at different ages and with various multiorgan complications. In this study, we aimed to analyze…Abstract Number: 2406 • ACR Convergence 2025
Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
Background/Purpose: Systematic lupus erythematosus (SLE) is an autoimmune disease with prognostic challenges due to its cyclic diversity. Artificial intelligence and machine learning (ML) has emerged…Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…
